Research supported by Bill & Melinda Gates Foundation will accelerate OHSU’s promising vaccine candidate
Researchers at OHSU's Vaccine and Gene Therapy Institute (VGTI) have been awarded an $8 million grant from the Bill & Melinda Gates Foundation to further develop a promising HIV vaccine candidate to combat the worldwide AIDS epidemic.
According to the World Health Organization, more than 34 million people have contracted HIV worldwide, and more than one-third of babies born in low- and middle-income countries already are infected.
The research will build on previous research conducted by Louis Picker, MD, and colleagues. Dr. Picker is Professor of Pathology, Associate Director of VGTI and Director of the VGTI’s vaccine program. In May of 2011, the Picker lab published findings that demonstrated how immune responses elicited by their vaccine candidate were able to completely control SIV (the monkey equivalent of HIV) among a significant number of exposed animals.
The full OHSU media release is available online.